At this October’s CPHI event being held in Milan, dsm-firmenich, is inviting stakeholders across the pharmaceutical market to ...

The company will introduce its innovative siliconized moulded glass vials, positioning itself as the only global supplier ...

At CPHI Milan 2024, Ardena will showcase its latest advancements in drug development and manufacturing, including the launch ...

During the show, Quotient Sciences CEO Thierry Van Nieuwenhove will share insights on how the company is adapting to new FDA ...

Large reduction in COGS: By 2025, EnzeneX 2.0 expects to produce 40 kg/1000 L batches at $40/gram, redefining FCCM economics. Lower operational costs and higher productivity can lead to up to 50% ...

The Barcelona-based startup Sequentia Biotech has raised €10 million ($11 million) in a Series A round to finance the ...

Artificial intelligence has emerged as a potential solution to inconsistent reporting of adverse events, which to this day ...

At CPHI Milan 2024, Ardena will showcase its latest advancements in drug development and manufacturing, including the launch of a state-of-the-art nanomedicines GMP facility in Oss, Netherlands.

These results back up results from the TEMPO-3 trial, which tested tavapadon as an add-on therapy to levodopa and which also ...

The US big pharma company Pfizer has voluntarily withdrawn the oral sickle cell disease treatment Oxbryta from the market and ...

The US biotech’s neurological drug candidate showed a reduction in disease progression of at least 50% and the company will ...

The small molecule drug arimoclomol (Miplyffa) has got the green light from the U.S. Food and Drug Administration (FDA) for ...